

VINCERO CAPITAL CORP.
Suite 2201 – 8 Smithe Mews
Vancouver, B.C.
V6B 0A5

Trading Symbol: TSX-V: VCO.P

Telephone: 604-619-0225

Fax: 604-980-6264

Vincero Capital Corp. Announces Filing of Filing Statement in Connection with Qualifying Transaction

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW.

March 19, 2021, Vancouver, British Columbia: Vincero Capital Corp. (“**Vincero**”) (TSX VENTURE:VCO.P) is pleased to announce that it has filed a filing statement dated March 17, 2021 (the “**Filing Statement**”) with the TSX Venture Exchange (“**TSXV**”) for the previously announced Transaction (as defined below), which is substantially described below and in Vincero’s press releases dated May 27, 2020, August 31, 2020, November 10, 2020, December 23, 2020, January 28, 2021 and March 16, 2021.

On August 31, 2020, Vincero entered into a definitive agreement with NewGen Therapeutics, Inc. (“**NewGen**”), as amended from time to time (the “**Business Combination Agreement**”). Pursuant to the Business Combination Agreement, Vincero will acquire certain worldwide rights (excluding the People’s Republic of China, Hong Kong and Taiwan) to the PARP Inhibitor Program Technology (the “**Significant Assets**”) to complete Vincero’s qualifying transaction (the “**Transaction**”) in accordance with the policies of the TSXV.

In connection with the Transaction, NewGen incorporated a subsidiary company in British Columbia, Rakovina Therapeutics Inc. (“**Rakovina**”). NewGen will transfer the Significant Assets to Rakovina in consideration for 30,000,000 Rakovina shares with a deemed value of \$6,000,000. Thereafter, Rakovina and Vincero’s wholly-owned subsidiary will amalgamate to become a wholly-owned subsidiary of Vincero. Upon completion of the Transaction, it is intended that Vincero will assume the name of Rakovina Therapeutics Inc. (the “**Resulting Issuer**”). The Resulting Issuer will continue the business of the Significant Assets. The Transaction was conditionally approved by the TSXV on March 12, 2021 and is expected to close on or about March 25, 2021.

Vincero and NewGen continue to work towards the satisfaction of all conditions precedent to closing of the Transaction.

About Vincero

Vincero was incorporated on May 6, 2019 under the laws of British Columbia, is a reporting issuer in the provinces of British Columbia and Alberta and is a “capital pool company” under the policies of the TSXV. It is intended that the Transaction, when completed, will constitute the “qualifying transaction” of Vincero for the purposes of Policy 2.4 – *Capital Pool Companies* of the TSXV.

Additional Information

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction. Vincero’s common shares are currently halted from trading and will remain halted until further notice. In connection with the Transaction and pursuant to TSXV requirements, Vincero has filed the Filing Statement on SEDAR (www.sedar.com), which contains details regarding the Transaction, the amalgamation, the private placement, NewGen, the Significant Assets, Vincero and the Resulting Issuer. Further details regarding the Transaction are disclosed in Vincero’s press releases dated May 27, 2020, August 31, 2020, November 10, 2020, December 23, 2020, January 28, 2021 and March 16, 2021.

The TSXV has in no way passed upon the merits of the Transaction and has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

The information contained or referred to in this press release relating to NewGen has been furnished by NewGen. Although Vincero has no knowledge that would indicate that any statement contained herein concerning NewGen is untrue or incomplete, neither Vincero nor any of its respective directors or officers assumes any responsibility for the

accuracy or completeness of such information. Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

Notice regarding forward-looking statements:

This release includes forward-looking statements regarding Vincero, NewGen, and their respective businesses, which may include, but is not limited to, statements with respect to the completion of the Transaction, the terms on which the Transaction are intended to be completed, the ability to obtain regulatory approvals, the proposed business plan of the Resulting Issuer and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this release, including completion of the Transaction, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the medical device industry, the risk that NewGen and Vincero may not obtain all requisite approvals for the Transaction, including the approval of the TSXV for the Transaction (which may be conditional upon amendments to the terms of the Transaction), failure to obtain regulatory approvals, economic factors, the equity markets generally and risks associated with growth and competition. Although Vincero and NewGen have attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Vincero and NewGen undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.’

Contact:

Vincero Capital Corp.

Alfredo De Lucrezia
President, CEO and Director
Tel: (604) 619-0225
Email: vincero-capitalcorp@shaw.ca

NewGen Therapeutics, Inc.

Jeffrey Bacha
Chief Executive Officer
Tel: (604) 317-7022
Email: jb@eohc.com